BTIG raised the firm’s price target on AtriCure (ATRC) to $54 from $52 and keeps a Buy rating on the shares. The company reported a “wow” quarter, exceeding expectations on the top and bottom as revenue growth accelerated to 16.5%, with results driven by new product launches across the Pain and Appendage Management franchises, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- AtriCure price target raised to $53 from $51 at Canaccord
- Atricure’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- AtriCure’s Strong Q2 2025 Performance and Raised Outlook
- AtriCure reports Q2 adjusted EPS (2c), consensus (16c)
- AtriCure cuts FY25 EPS view to (39c)-(34c) from (55c)-(50c), consensus (51c)